|
|
| (4 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fondaparinux#Contraindications]] |
| {{Fondaparinux}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Contraindications==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ARIXTRA is contraindicated in the following conditions:
| | [[Category: Anticoagulants]] |
| | |
| :*Severe [[renal impairment]] ( [[creatinine clearance]] '''[CrCl] < 30 mL/min'''). [See Warnings and Precautions and Use in Specific Populations (]
| |
| :*Active major [[bleeding]]. | |
| :*Bacterial [[endocarditis]].
| |
| :*[[Thrombocytopenia]] associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.
| |
| :*'''Body weight < 50 kg''' ( [[venous thromboembolism]] [VTE] prophylaxis only) [see Warnings and Precautions ].
| |
| :*History of serious [[hypersensitivity]] reaction (e.g., [[angioedema]], [[anaphylactoid]]/[[anaphylactic]] reactions) to ARIXTRA.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref> | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]] | |